New hope for women with resistant ovarian cancer
NCT ID NCT07109414
Summary
This study is testing whether adding an experimental drug called NP-G2-044 (Prilukae) to standard chemotherapy (PLD) works better than the standard chemo alone for women with platinum-resistant ovarian cancer. The goal is to find the best dose of the new combination and see if it helps control the cancer longer and with fewer side effects. About 380 women whose cancer has stopped responding to platinum-based treatments will participate.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLATINUM RESISTANT OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
HonorHealth Cancer Care
Phoenix, Arizona, 85016, United States
-
Optimum Clinical Research Group, LLC
Albuquerque, New Mexico, 87109, United States
-
Trials365
Shreveport, Louisiana, 71133, United States
-
University Of Wisconsin Carbone Cancer Center
Madison, Wisconsin, 53792-9988, United States
-
University of Pennsylvania Health System, Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania, 19104-5127, United States
-
Utah Cancer Specialists
Salt Lake City, Utah, 84106, United States
Conditions
Explore the condition pages connected to this study.